Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2020 Net Income-$1.32M-$1.32MN/M vs Q3 2020 EPS Diluted-$1.17-$1.17N/M vs Q3 2020 Operating Income-$676,252N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
ended May 31, 2021 · filed Jul 14, 2021 · 44 d after period end